Trojan horses encapsulated by a TRODELVYᵀᴹ cell membrane in a green, cellular environment.

Results

TRODELVY PROVIDED IMPRESSIVE RESPONSES

Overall response rate*

Overall Response Rate = 33%
Overall Response Rate = 33%
  • 34.3% ORR based on BICR (95% CI: 25.4; 44.0)1†

Duration of response

Duration of response rate = 7.7 median months
Duration of response rate = 7.7 median months
  • 9.1 months DOR based on BICR (95% CI: 4.6; 11.3)1†
BICR: important limitations

Blinded, independent, central review (BICR) of staging scans was obtained for the 56 patients determined to have a CR, PR, or ≥20% reduction in target lesions by investigator assessment. Since the BICR analyses were conducted in a subgroup of preselected patients based on investigator assessment, the results are subject to bias and should be interpreted with caution.

Tumor imaging occurred every 8 weeks initially with confirmatory scans to confirm responses 4 to 6 weeks after the first apparent response.

CI=confidence interval; CR=complete response; DOR=duration of response; ORR=overall response rate; PR=partial response.

*Based on investigator assessment. Reference: 1. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741-751.